Serum prolidase levels in Graves' disease without ophthalmopathy and its association with oxidative status

Journal of Endocrinological Investigation

Volumn 38, Issue 11, 2015, Pages 1167-1173

  Korkmaz, H ^a   Tabur, S ^a   Ozkaya, M ^a   Oguz, E ^b   Aksoy, N ^b   Akarsu, E ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Graves' disease; Hashimoto's thyroiditis; Oxidative status; Prolidase

Indexed keywords

ANTIOXIDANT; PROLINE DIPEPTIDASE; THIOL DERIVATIVE; DIPEPTIDASE;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EUTHYROIDISM; FEMALE; GENERAL PATHOLOGICAL PARAMETERS; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROLIDASE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TOTAL ANTIOXIDANT STATUS; TOTAL OXIDATIVE STRESS; BLOOD; MIDDLE AGED; PHYSIOLOGY;

ADULT; DIPEPTIDASES; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; SULFHYDRYL COMPOUNDS;

EID: 84944059985     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-015-0278-7     Document Type: Article

References (25)

1. Menconi F, Marcocci C, Marinò M (2014) Diagnosis and classification of Graves' disease. Autoimmun Rev 13:398-402
2. Douglas RS, Gupta S (2011) The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol 22:385-390
3. Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2015) Role of genetic and non-genetic factors in the etiology of Graves' disease. J Endocrinol Invest 38:283-294
4. Khalilzadeh O, Noshad S, Rashidi A, Amirzargar A (2011) Graves' ophthalmopathy: a review of immunogenetics. Curr Genomics 12:564-575
5. Winsz-Szczotka K, Komosińska-Vassev K, Kuźnik-Trocha K, Olczyk K (2014) Antioxidant activity and structural modifications of serum chondroitin sulfate in Graves' disease. Clin Biochem 47:19-24
6. Cechowska-Pasko M, Pałka J, Wojtukiewicz MZ (2006) Enhanced prolidase activity and decreased collagen content in breast cancer tissue. Int J Exp Pathol 87:289-296
7. Horoz M, Aslan M, Bolukbas FF, Bolukbas C, Nazligul Y, Celik H, Aksoy N (2010) Serum prolidase enzyme activity and its relation to histopathological findings in patients with non-alcoholic steatohepatitis. J Clin Lab Anal 24:207-211
8. Zarković M (2012) The role of oxidative stress on the pathogenesis of Graves' disease. J Thyroid Res. doi: 10.1155/2012/302537
9. Erel O (2004) A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 37:112-119
10. Erel O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38:1103-1111
11. Aycicek A, Erel O, Kocyigit A (2005) Decreased total antioxidant capacity and increased oxidative stress in passive smoker infants and their mothers. Pediatr Int 47:635-639
12. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77
13. Myara I, Charpentier C, Lemonnier A (1982) Optimal conditions for prolidase assay by proline colorimetric determination: application to imminodipeptiduria. Clin Chim Acta 125:193-205
14. Chinard FP (1952) Photometric estimation of proline and ornithine. J Biol Chem 199:91-95
15. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839
16. Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, Masarik M, Prusa R, Kizek R (2010) Matrix metalloproteinases. Curr Med Chem 17:3751-3768
17. Galil SM, El-Shafey AM, Hagrass HA, Fawzy F, Sammak AE (2014) Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. Int J Rheum Dis. doi: 10.1111/1756-185X.12434
18. Odabasi M, Yesil A, Ozkara S, Paker N, Ozkan S, Eris C, Yildiz MK, Abuoglu HH, Gunay E, Tekeşin K (2014) Role of human neutrophil gelatinase associated lipocalin (NGAL) and Matrix Metalloproteinase-9 (MMP-9) overexpression in neoplastic colon polyps. Int J Clin Exp Med 7:2804-2811
19. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ (2004) Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 42:121e31
20. Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M, Pöllänen P, Lehtimäki T (2004) Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome. Rheumatology (Oxford) 43:1476-1479
21. Mys̈liwiec J, Adamczyk M, Pawłowski P, Nikołajuk A, Górska M (2007) Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves' ophthalmopathy. Endokrynol Pol 58:105-109
22. Marcocci C, Bartalena L (2013) Role of oxidative stress and selenium in Graves' hyperthyroidism and orbitopathy. J Endocrinol Invest 36:15-20
23. Altindag O, Erel O, Aksoy N, Selek S, Celik H, Karaoglanoglu M (2007) Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. Rheumatol Int 27:339-344
24. Hilali N, Vural M, Camuzcuoglu H, Camuzcuoglu A, Aksoy N (2013) Increased prolidase activity and oxidative stress in PCOS. Clin Endocrinol (Oxf) 79:105-110
25. Gecit I, Aslan M, Gunes M, Pirincci N, Esen R, Demir H, Ceylan K (2012) Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer. J Cancer Res Clin Oncol 138:739-743